EUCTR2008-002608-25-AT进行中（未招募）1 期
A Phase I/II randomised, double-blind, multi-centre study to assess the efficacy of AZD2281 when given in combination with paclitaxel in the 1st or 2nd line treatment of patients with metastatic Triple Negative Breast Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Provision of fully informed consent prior to any study specific procedures
- •2.Patients must be > 18 years of age
- •3.Female patients with histologically or cytologically diagnosed metastatic triple-negative breast cancer
- •-Oestrogen, progesterone and HER2 negative advanced adenocarcinoma of the breast defined as:
- •§For ER, PR status: Allred<3 or ER, PR IHC 0 and
- •§For HER2 status: IHC 0 or 1+ or FISH negative; if IHC 2+, need negative FISH confirmation.
- •4.Phase II only - At least one lesion, not irradiated within 12 weeks of the first administration of study treatment, that can be accurately measured as ³ 10 mm in the longest diameter with spiral computed tomography (CT) scan or as ³ 20 mm with conventional techniques according to RECIST (Conventional CT, MRI) and which is suitable for accurate repeated measurements.
- •5.Patients must have normal organ and bone marrow function measured within 7 days prior to administration of study treatment as defined below:
- •-Haemoglobin = 9.0 g/dL
- •-Absolute neutrophil count (ANC) = 1500 x 106/L
- •-White blood cells (WBC) > 3x109/L
- •-Platelet count = 100, 000 x 106/L
- •-Total bilirubin = 1.5 x institutional upper limit of normal
- •-AST (SGOT)/ALT (SGPT) = 2.5 x institutional upper limit of normal unless liver metastases are present in which it must be = 5x ULN
- •-Creatinine clearance (Cockcroft-Gault) within normal range (> 60 mL/min).
- •-Serum creatinine = 1.5 x institutional upper limit of normal (ULN)
- •6.ECOG performance status = 2 for breast (see Appendix F)
- •7.Patients must have a life expectancy = 16 weeks.
- •8.Evidence of non-childbearing status: negative urine or serum pregnancy test within 7 days of study treatment for women of childbearing potential, or postmenopausal status
- •Postmenopausal is defined by any one of the following:
- •§natural menopause with last menses >1 year ago;
- •§radiation-induced oophorectomy with last menses >1 year ago,
- •§chemotherapy-induced menopause with >1 year interval since last menses,
- •§serum follicle stimulating hormone, lutenising hormone and plasma oestradiol levels in the post menopausal range for the institution,
- •§or surgical sterilisation (bilateral oophorectomy or hysterectomy).
- •9.Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.
- •10.Formalin fixed, paraffin embedded tumour sample from the primary or recurrent cancer must be available for central testing. If an archived tumour sample is not available the patient will not be eligible for the study.
- •For inclusion in genetic research, patients must fulfil the following criterion:
- •1.Provision of informed consent for genetic research
- •If a patient declines to participate in the genetic research, there will be no penalty or loss of benefit to the patient. The patient will not be excluded from other aspects of the study described in this Clinical Study Protocol, so long as they consent to that part.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Previous treatment with AZD2281
- •2.Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for = 5 years.
- •3.Patients receiving any chemotherapy, radiotherapy (except for palliative reasons), within 2 weeks from the last dose prior to study entry (or a longer period depending on the defined characteristics of the agents used). The patient can receive a stable dose of bisphosphonates for bone metastases, before and during the study as long as these were started at least 4 weeks prior to enrolment.
- •4.Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence of brain metastases is not required. The patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to enrolment.
- •5.More than one prior chemotherapy for advanced disease and/or extensive irradiation leading to bone marrow deficiency. Extensive radiotherapy would be that involving 30% of the bone marrow e.g. whole pelvis or half spine.
- •6.Major surgery within 4 weeks of starting the study and patients must have recovered from any effects of any major surgery.
- •7.Pre-existing peripheral neuropathy > grade 1.
- •8.Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months), myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent.
- •9.Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication (e.g. partial bowel obstruction or malabsorption)
- •10.Patients requiring treatment with inhibitors or inducers of CYP3A4 (see Section 6.4.1 for guidelines and wash out periods).
- •11.Patients requiring treatment with inhibitors or inducers of CYP2C8 (see Section 6.4.2 for guidelines and wash out periods).
- •12.Pregnant or breastfeeding women.
- •13.Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV).
- •14.Patients with known hepatic disease (i.e., Hepatitis B or C).
- •15.Persistent toxicities (grade 2 or greater) from any cause
- •16.Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
- •17.Previous randomisation to treatment in the present study
- •18.Treatment with any investigational product during the last 14 days (or a longer period depending on the defined characteristics of the agents used)
- •19.Patient with a history of hypersensitivity reactions to paclitaxel or other drugs formulated in Cremophor® EL (polyoxyethylated castor oil)
- •20.Patients with a known hypersensitivity to AZD2281 or any of the excipients of the product.
- •21.Patients currently experiencing seizures or who were currently being treated with only anti-epileptics for seizures (use of anti-epileptic drugs to control pain is allowed in patients not suffering from seizures unless drug is excluded due to CYP3A4 induction - phenytoin, carbamazepine, phenobarbitone, see Section 6.4.1
- •22.Optional pharmacogeneti
研究者
相似试验
进行中（未招募）
1 期
A Phase I/II randomised, double-blind, multi-centre study to assess the efficacy of AZD2281 when given in combination with paclitaxel in the 1st or 2nd line treatment of patients with metastatic Triple Negative Breast CancerMetastatic Triple Negative Breast CancerMedDRA version: 9.1Level: LLTClassification code 10055113Term: Breast cancer metastaticEUCTR2008-002608-25-DKAstraZeneca AB270
进行中（未招募）
1 期
A Phase I/II randomised, double-blind, multi-centre study to assess the efficacy of AZD2281 when given in combination with paclitaxel in the 1st or 2nd line treatment of patients with metastatic Triple Negative Breast CancerEUCTR2008-002608-25-BEAstraZeneca AB270
进行中（未招募）
1 期
A Phase I/II randomised, double-blind, multi-centre study to assess the efficacy of AZD2281 when given in combination with paclitaxel in the 1st or 2nd line treatment of patients with metastatic Triple Negative Breast CancerMetastatic Triple Negative Breast CancerMedDRA version: 9.1Level: LLTClassification code 10055113Term: Breast cancer metastaticEUCTR2008-002608-25-CZAstraZeneca AB19
进行中（未招募）
不适用
Safety and immunogenicity of new formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib vaccine (GSK217744) in primary infant vaccination.Primary immunization of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b (Hib) diseases.MedDRA version: 13.1Level: PTClassification code 10043376Term: TetanusSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 13.1Level: LLTClassification code 10018952Term: Haemophilus influenzae infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 13.1Level: PTClassification code 10034738Term: PertussisSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 13.1Level: PTClassification code 10019731Term: Hepatitis BSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 13.1Level: PTClassification code 10013023Term: DiphtheriaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 13.1Level: PTClassification code 10036012Term: PoliomyelitisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-021569-58-FIGlaxoSmithKline Biologicals720
进行中（未招募）
不适用
Investigation of Cogane (PYM50028) in early stage Parkinson's diseaseEUCTR2010-018534-44-HUPhytopharm plc408